Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 14, 2014
NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jan 8, 2014
NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 20, 2013
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 11, 2013
NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 8, 2013
NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 7, 2013
NATICK, Mass., Dec. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 5, 2013
NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 2, 2013
NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Nov 8, 2013
NATICK, Mass., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class...
-
Nov 5, 2013
Karyopharm Therapeutics Announces Pricing of Initial Public OfferingNATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on...
-
Oct 22, 2013
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical...
-
Oct 7, 2013
Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public OfferingNatick, Mass. – October 7, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Oct 3, 2013
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of DirectorsNatick, Mass. – October 3, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Aug 7, 2013
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research...
-
Jul 31, 2013Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
Natick, Mass. – July 31, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of...
-
Jun 2, 2013
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual MeetingNatick, Mass....
-
May 28, 2013
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA CongressNatick, Mass. – May 28, 2013 – Karyopharm Therapeutics Inc., a leader...
-
May 20, 2013
Karyopharm Therapeutics Raises $48.2 Million in Series B FinancingNatick, Mass. – May 20, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today...
-
May 15, 2013
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual MeetingNatick, Mass. – May 15, 2013 – Karyopharm Therapeutics...
-
May 9, 2013
Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR)Natick, Mass. May 9, 2013...
-
Mar 26, 2013
Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR)...
-
Feb 5, 2013
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & DevelopmentNatick, Mass. February 5th 2013 Karyopharm...
-
Jan 17, 2013
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)Natick, Mass....
-
Dec 4, 2012
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)Natick, Mass....
-
Nov 13, 2012
Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) MeetingNatick, Mass....
-
Nov 12, 2012Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Natick, Mass. November 12, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Jul 25, 2012
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced CancersNatick, Mass. July 25, 2012...
-
May 25, 2012
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) MeetingNatick, Mass. May...
-
May 8, 2012
Karyopharm Therapeutics Announces Appointment of Cofounder Dr. Ronald DePinho to the National Academy of SciencesNatick, Mass. May 8, 2012 Karyopharm Therapeutics Inc., a leader in the new field...
-
Mar 15, 2012
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American...
-
Nov 8, 2011
Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American...
-
Nov 2, 2011
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for CancerNatick, Mass. – November 2, 2011...
-
Oct 11, 2011Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Natick, Mass. – October 11, 2011 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has initiated an exclusive collaboration in the area of Selective...
-
Jan 6, 2011
Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation TreatmentsNorwalk, Conn. – January 6, 2011 The Multiple Myeloma Research Foundation (MMRF) today...
-
Jan 5, 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive OfficerNewton, Mass. – January 5, 2011 Karyopharm Therapeutics Inc., a pioneer and leader in the new field of...
-
Nov 3, 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other DisordersNewton, Mass. – November...